Drug Database
AN

antofloxacin hydrochloride

✓ Approved

Anhui Globe Pharmaceutical · TOP2A · Small Molecule

What is antofloxacin hydrochloride?

antofloxacin hydrochloride is a small molecule developed by Anhui Globe Pharmaceutical. It is approved for therapeutic indications via injectable (others) or intravenous (iv) or oral (po).

Drug Profile

CompanyAnhui Globe Pharmaceutical
Drug ClassSmall Molecule
Molecular TargetTOP2A
RouteInjectable (Others), Intravenous (IV), Oral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Anhui Globe Pharmaceutical

Mechanism of Action

Molecular Targets

antofloxacin hydrochloride acts on 1 molecular target:

TOP2ADNA topoisomerase II alpha (TOP2alpha, TOPIIA)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

antofloxacin hydrochloride is developed for 3 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsPneumonia✓ Approved
Infections and infestationsUrinary tract infection✓ Approved
Infections and infestationsStreptococcal infection✓ Approved

Related Research Articles

PubMedZhonghua nan ke xue = National journal of andrology2026-11-11

[Effect of esketamine on anesthesia and postoperative analgesia in patients with prostate resection: Based on oxidative stress response].

Liu Dapeng D, Feng Lingling L, Yao Qun Q, Li Jianwei J et al.

Objective To investigate the effects of esketamine on postoperative analgesia, cognitive function, oxidative stress and safety in patients with electroprostatectomy. Methods One hundred and twenty patients who underwent electroprostatectomy in Zaozhuang Municipal Hospital from October 2021 to May 2022 were selected and divided into experimental group and control group according to the different treatment, with 60 cases in each group. The patients in control group were treated with routine sufentanil during the operation. And esketamine hydrochloride was used in the experimental group at the dosage of 0.2 mg/kg 10 minutes before the end of the operation. VAS score and MMSE score were recorded at 0.5, 2, 4 and 12 h after surgery. The levels of oxidative stress indexes including NE and GSH-Px were compared between the two groups, and the postoperative urinary tract irritation and adverse reactions were analyzed. Results There was significant difference in VAS score between the two groups at 0.5 h and 2 h after surgery (P<0.05), but no significant difference at 4 h and 12 h (P>0.05). There was significant difference in MMSE score at 0.5 h after operation (P<0.05). The scores of urethral irritation in the experimental group were significantly lower than those in the control group at 0.5 h and 2 h after operation (P<0.05), and the inhibition effect on urethral irritation was significant. After anesthesia, the levels of NE and GSH-Px in experimental group showed a more dramatic improvement compared to control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion Esketamine has good postoperative analgesic effect in elderly patients undergoing transurethral resection of prostate with a temporary effect on early postoperative cognitive function, which alleviates symptoms of urinary duct irritation and oxidative stress caused by surgery.

PMID 43012260
Read full article →
PubMedZhonghua nan ke xue = National journal of andrology2026-11-11

[Clinical efficacy and mechanism of Liniao Tonglin decoction in treating UU-infected oligoasthenospermia with dampness-heat pouring down syndrome].

Zhu Fanyu F, Li Ninghua N, Yang Wentao W

Objective To explore the clinical effect and mechanism of Liniao Tonglin decoction on oligoasthenospermia caused by Ureaplasma urealyticum (UU) infection with dampness-heat pouring down syndrome. Methods Eighty-eight patients were randomly divided into control group and observation group, with 44 cases in each group. The patients in control group were treated with doxycycline hydrochloride enteric-coated capsules and doxycycline tablets. While the patients in observation group were treated with Liniao Tonglin decoction on the basis of the treatment given to the control group. Both groups were treated for 14 days. Sperm concentration, total sperm count, progressive motility sperm rate(PR%), sperm motility rate（［PR+NP］%）, seminal plasmic elastase, interleukin-6(IL-6), interleukin-17(IL-17) levels TCM syndrome score and negative conversion rate of UU were compared between the two groups before and after the treatment. Results The overall efficacy rate of the observation group was significantly higher than that in the control group (86.05% vs 66.67% , χ2=4.435, P<0.05). UU negative conversion rate was also superior in the observation group (95.35% vs 88.10%，P>0.05). The increases in sperm concentration, total count, PR%, and （PR+NP）% (P<0.05) exhibited in both of two groups after the treatment, with significantly greater improvements in the observation group (P<0.05). The levels of seminal elastase, IL-6, IL-17 and TCM syndrome scores declined in both groups (P<0.05), with greater improvements in the observation group as well (P<0.05). Conclusion Liniao Tonglin decoction combined with antibiotics improves the count and motility of sperm and TCM syndrome score of oligoasthenospermia induced by UU infection with dampness-heat pouring down syndrome, increases the negative rate of UU, inhibits the expression of inflammatory factors, and changes the patency of reproductive tract and the living environment of sperm.

PMID 43012219
Read full article →
PubMedZhonghua zhong liu za zhi [Chinese journal of oncology]2026-11-11

[Mitoxantrone hydrochloride liposomes combined with R-GDP regimen in the treatment of relapsed/refractory diffuse large B-cell lymphoma: a single-arm, multicenter, exploratory clinical study].

Ma L L, Zhao J J, Wang J R JR, Zheng M J MJ et al.

Objective: To evaluate the efficacy and safety of the mitoxantrone liposome combined with R-GDP regimen (R-GDP-Mito regimen) in the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Methods: From May 2023 to September 2025, a total of 33 patients with relapsed/refractory DLBCL(R/R DLBCL) were enrolled from multiple centers, including Shanxi Provincial Cancer Hospital, Jincheng People's Hospital of Shanxi Province, Heping Hospital Affiliated to Changzhi Medical College, and Datong Second People's Hospital of Shanxi Province. All patients received 2 to 6 cycles of the R-GDP-Mito regimen. The short-term and long-term efficacy as well as adverse events were analyzed. Results: Among the 33 patients, 16 achieved complete remission (CR), 11 achieved partial remission (PR), 3 had stable disease (SD), and 3 experienced disease progression (PD). The objective response rate (ORR) was 81.8% (27/33), with a 95% CI of 61.4% to 92.3%. The median time to best response was 1.9 months. With a median follow-up of 4.8 months, disease progression was observed in 4 patients, and 5 patient deaths were recorded, attributed to disease progression and severe pulmonary infection, respectively. The median progression-free survival (PFS) was not reached, while the median overall survival (OS) was 16.1 months. The 1-year PFS and OS rates were 56.6% and 90.5%, respectively. All 33 patients experienced adverse events (AEs). Hematological AEs occurred in 60.6% (20/33) of patients, and non-hematological AEs occurred in 81.8% (27/33) of them. Conclusion: The R-GDP-Mitoregimen demonstrates high antitumor activity and well-controlled safety profile in R/R-DLBCL patients, offering a promising new therapeutic option, particularly for those unable to immediately access or tolerate novel targeted or immunotherapy regimens.

PMID 43010748
Read full article →
PubMedChemphyschem : a European journal of chemical physics and physical chemistry2026-11-10

Interconversion Among Different Forms of Lumichrome in Aqueous Pluronic P84 Solutions: Effects of Glucose, Urea, and Guanidine Hydrochloride.

Giri Suman Kalyan SK, Manna Sagar Kumar SK, Seth Debabrata D

This work represents a detailed photophysical investigation of Lumichrome (LuC) in a hydrophobic triblock copolymer, Pluronic P84, as a function of the kosmotropic osmolyte, glucose, and the chaotropic osmolytes, urea and guanidine hydrochloride (GH). The spectral characteristics of LuC demonstrate that, addition of glucose lowers the critical micelle temperature (CMT) of P84, suggesting that dehydration of poly (propylene oxide) (PPO) blocks of P84 through the "sugaring-out" phenomena promotes micellization. In contrast, urea and GH increase the CMT of P84, indicating enhanced polymer hydration and weakened hydrophobic interactions that hinder micellization. Fluorescence spectra of LuC illustrate that osmolytes and temperature modulate the microenvironment of LuC. This was confirmed by finding different forms of LuC in P84 micelles with help of steady state and time resolved fluorescence emission studies. The emission spectrum shows a blueshift as temperature increases. The addition of glucose produced no significant shift in the dominant ~460 nm emission band, while additional emission features/shoulders appeared around ~530 and ~436 nm. Fluorescence lifetime data suggest that, along with 7,8-dimethylalloxazine (DMAL) form, A10, A3 and 7,8-dimethylisoalloxazine (DMIS) species of LuC may also exist within the P84 micelle. Fluorescence anisotropy measurements revealed distinct osmolyte-dependent rotational dynamics, indicating changes in the microenvironment surrounding LuC.

PMID 43004135
Read full article →
PubMedAAPS PharmSciTech2026-11-10

Eutectic Mixture as a Novel Approach to Improve Compression Properties of Metformin Hydrochloride.

Elsergany Ramy N RN, Tan Yee Seng YS, Nair Rajesh S RS, Ho Paul Chi-Lui PC et al.

Metformin hydrochloride (MET), an antidiabetic medication, possesses poor compression properties and severe elastic recovery, hindering its formulation via direct compaction. This study engineered MET eutectic mixture and cocrystals using freeze-drying and evaluated them for overcoming these compression liabilities and minimizing punch sticking propensity. Niacinamide (NI), a flexible carboxamide micronutrient beneficial in diabetes management, was evaluated alongside D-Mannitol (MAN), a brittle polyol benchmark excipient, at 1:1 and 1:2 molar ratios. Solid-state characterization (PXRD, FTIR, DSC and TGA) confirmed that both adjuvants yield a eutectic mixture at a 1:1 ratio and a distinct cocrystal phase at a 1:2 ratio. Morphologically, the MET-NI systems exhibited unique layered microstructures. Mechanical profile assessment showed that MET-NI eutectic mixture and cocrystals drastically improved MET plasticity, showing significantly reduced yield pressure via Heckel analysis compared to their corresponding physical mixtures. Consequently, the MET-NI systems displayed enhanced compactibility and tabletability, producing mechanically stable tablets at high drug-coformer loadings (99.5% w/w). Conversely, the MET-MAN formulations exhibited dominant brittle deformation, resulting in severe tablet lamination and capping at compaction pressures exceeding 150 MPa. Furthermore, punch sticking assessment revealed that the enhanced internal tablet strength (API:coformer - API:coformer bonding interaction) of MET-NI eutectics and cocrystals reduced punch sticking mass up to 10-fold compared to the physical mixture. This work demonstrates that particle engineering, particularly utilizing eutectic mixture approach via freeze-drying with flexible carboxamides like niacinamide, presents a highly viable approach for modifying the micromechanical properties of problematic drugs to facilitate seamless large-scale direct compaction manufacturing.

PMID 43004033
Read full article →
PubMedJournal of medical case reports2026-11-10

Severe toxicity following supratherapeutic co‑ingestion of duloxetine and dexzopiclone in a young patient with major depressive disorder: a case report.

Jinmin Wang W, Jushan Lin L, Min Lin L, Yunhai Liao L et al.

A 23-year-old female with major depressive disorder (MDD), non-suicidal self-injury and generalized somatic pain was treated with duloxetine hydrochloride enteric-coated capsules, quetiapine fumarate tablets, and aripiprazole orally disintegrating tablets, with significant pain relief. Dexzopiclone tablets were added for insomnia, and all medications were kept by her mother. Despite compliance with medication, the patient had persistent suicidal ideation and secretly ingested 4500 mg duloxetine and 63 mg dexzopiclone on February 18, 2021. She was rushed to hospital 3.5 h later and received emergency treatment including oxygen inhalation, gastric lavage and high-dose vitamin B6/C infusion. Combined with psychological suggestion and cognitive therapy, she recovered and was discharged 12 days later. At the 4.5-year follow-up (September 2025), the patient had discontinued lurasidone and quetiapine, both of which were started during index hospitalization; she demonstrated normal daily functioning with no recurrent suicidal ideation or self-injury. To our knowledge, severe toxicity from co-ingestion of supratherapeutic doses of duloxetine and dexzopiclone has been rarely documented; this report details the clinical management and differential diagnosis strategies for this rare drug-combination toxicity.

PMID 43004457
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about antofloxacin hydrochloride